Serdar Karakaya - Publications

Adding immunotherapy to chemotherapy may improve survival after SCLC transformation in EGFR-mutant NSCLC: a multicenter real-world study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 14, 2026

KRAS Mutation Subtypes, Co-Mutations, PD-L1 Expression, and Survival Outcomes in Non-Small Cell Lung Cancer.

Journal: Journal of clinical medicine

Published: June 05, 2026

Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study.

Journal: Cancers

Published: May 12, 2026

Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study).

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: March 01, 2026

Prognostic Value of STAS, Lymph Node Metastasis, and VPI in NSCLC ≤ 4 cm Treated with Lobectomy.

Journal: Journal of clinical medicine

Published: November 20, 2025

Correction: Kalkan et al. Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study. Medicina 2025, 61, 638.

Journal: Medicina (Kaunas, Lithuania)

Published: October 07, 2025

Do Inflammatory and Nutritional Markers Predict Prognosis in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab.

Journal: Journal of inflammation research

Published: June 12, 2025

Impact of Treatment Duration in First-Line Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer: A Multicenter Real-World Retrospective Study.

Journal: Medicina (Kaunas, Lithuania)

Published: June 03, 2025

Prognostic Impact of Clinicopathological and Inflammatory Markers in Surgically Treated Pulmonary Invasive Mucinous Adenocarcinoma.

Journal: Seminars in thoracic and cardiovascular surgery

Published: May 04, 2025

Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group.

Journal: Clinical lung cancer

Published: May 01, 2025

Dynamic Alteration of HALP Score as a Predictor in Patients with Receiving Immunotherapy for Advanced Non-Small Cell Lung Cancer.

Journal: Medicina (Kaunas, Lithuania)

Published: April 27, 2025

Nutritional Indexes and Their Variations as Predictors of Atezolizumab Plus Chemotherapy Efficacy in Extensive-Stage Small Cell Lung Cancer: A Turkish Oncology Group Study.

Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)

Published: March 22, 2025